GLPwatch
Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight.
Diabetes Res Clin Pract · 2024
Last updated 2026-05-28A study tested the effects of a low dose (0.5 mg) of the drug semaglutide, taken once a week, in adults with type 1 diabetes who also had excess weight. The research focused on how this dose might impact their health, though the abstract does not provide specific results.
AI summary of the abstract below.
| Journal | Diabetes Res Clin Pract, 2024 |
|---|---|
| Citations | 18 |
| Relative citation ratio | 3.56 |
| NIH percentile | 87 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Obesity is a prevalent problem in people living with T1D (PwT1D), and it has been linked to cardiovascular disease in this population. The use of low dose weekly Semaglutide (0,5 mg) was evaluated in a cohort of PwT1D and excess weight.
Verbatim abstract via PubMed 38403174 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.